UBS AM
PSTX

UBS AM’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

UBS AM’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-39,000
Closed -$120K – 2701
2023
Q2 		$120K Hold
39,000
– – ﹤0.01% 2628
2023
Q1 		$120K Buy
+39,000
New +$234K ﹤0.01% 2628
2020
Q4 		– Sell
-277,071
Closed -$2.46M – 2595
2020
Q3 		$2.46M Buy
+277,071
New +$3.15M ﹤0.01% 1466

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

UBS AM's PSTX Position: Q3 2023 in Review

UBS AM sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q3 2023, closing a stake of 39,000 shares — an estimated $120K sold.

UBS AM first reported a position in PSTX in Q3 2020 and held it in 3 quarters. The position peaked at $2.46M in Q3 2020. 86 funds tracked by Wall St. Rank hold PSTX as of Q3 2023.

  • UBS AM reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • UBS AM sold 39,000 Poseida Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $120K.
  • UBS AM first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • UBS AM's Poseida Therapeutics, Inc. Common Stock position peaked at $2.46M in Q3 2020.
  • 86 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q3 2023.

Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.